Medline Inc. Class A (MDLN)
NASDAQ: MDLNHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MDLN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $48.75B
- P/E (TTM)
- 84.18
- Forward P/E
- 23.98
- EPS (TTM)
- $0.44
- Dividend yield
- None
- 52-week range
- 31.37 – 50.88
- Day range
- 36.94 – 38.37
- Volume / Avg
- 9.33M / 9.55M
- Beta
- —
- Shares outstanding
- 878.66M
52-week range
MDLN stock today
Medline (MDLN) closed at $37.04 on Nov 20, down 2.11% (-$0.80), versus the S&P 500's 3.70% decline. Shares are 27.2% below their 52-week high of $50.88, set on Feb 25, 2026 and 18.1% above the 52-week low of $31.37, in the middle of the past year's range. MDLN is down 11.8% year to date, underperforming the S&P 500 (+1.2%).
At 84.2x trailing earnings, Medline trades above the peer-group median of 36.6x. Its forward P/E of 24.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Medline
Company profileMedline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. James M. Boyle
- Headquarters
- Northfield, IL
- Employees
- 45,000
- IPO year
- 2025
- Website
- medline.com
Financial highlights
Full financialsIn fiscal 2025, Medline generated $28.43 billion in revenue. Net income was $1.16 billion (+0.5% year over year), for a net margin of 4.1% versus a median of 2.8% in the prior 3 years. Gross margin was 26.4% and operating margin 7.8%.
| Fiscal year | FY 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue | $28.43B | — | $25.51B | $23.23B |
| Growth | — | — | +9.80% | — |
| Net income | $1.16B | $1.15B | $1.16B | $234.00M |
| EPS (diluted) | $-0.01 | — | — | — |
Analyst forecast
ForecastConsensus (25 analysts)
buy
Avg. price target
$45.75+23.52%
- Strong buy 6
- Buy 15
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.22 vs $0.32
- Surprise
- -31.25%
MDLN news
All MDLN news- Medline launches right-sized Ranpak packaging solutions in two key distribution centersPR Newswire
- Medline stock falls as shareholders price secondary offeringInvesting.com
- Why is Medline stock sliding today?Investing.com
- Medline prices 60M share secondary offering at $35.50/share alongside $200M concurrent repurchaseSeeking Alpha
- Medline Prices Secondary Offering Of 60 Mln Class A Shares At $35.50 Per ShareNasdaqMDLN, LEN.B
- Medline Inc. announces pricing of secondary offering of Class A common stockGlobeNewswire
- Medline Inc. announces launch of secondary offering of Class A common stockGlobeNewswire
- Medline bed deaths rise to sevenSeeking Alpha
Medline peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BDXBecton Dickinson and Company | 212.78 | +0.05% | $57.96B | vs MDLN |
| BSXBoston Scientific Corporation | 41.98 | -2.35% | $60.85B | vs MDLN |
| RMDResMed Inc. | 235.63 | -0.53% | $33.14B | vs MDLN |
| DXCMDexCom Inc. | 79.32 | -1.08% | $29.58B | vs MDLN |
| WSTWest Pharmaceutical Services Inc. | 390.30 | -1.61% | $27.19B | vs MDLN |
| SOLVSolventum Corporation | 84.50 | -1.52% | $14.36B | vs MDLN |
| GKOSGlaukos Corporation | 237.31 | -0.33% | $14.05B | vs MDLN |
| BAXBaxter International Inc. | 25.39 | 0.00% | $13.14B | vs MDLN |
Indexes, lists and sector
Medline stock FAQ
What is Medline's stock price today?
MDLN last traded at $37.04 as of Nov 20, 4:00 PM EST, down 2.11% on the day. Prices are delayed at least 15 minutes.
What is MDLN's P/E ratio?
MDLN trades at a trailing P/E ratio of 84.18 and a forward P/E of 23.98, compared with a median of 36.6 for its closest peers.
Who is Medline's CEO?
Mr. James M. Boyle is the chief executive officer of Medline Inc. Class A, which has about 45,000 employees.
What is the MDLN 52-week high?
The 52-week high for MDLN is $50.88 and the 52-week low is $31.37. The stock is currently 27.2% below its high.